Socioeconomic trends in hospitalization for multiple sclerosis

Neuroepidemiology

Volumn 35, Issue 2, 2010, Pages 93-99

  Lad, Shivanand P ^a,b   Chapman, Christopher H ^a,b   Vaninetti, Michael ^a,b   Steinman, Lawrence ^a,b   Green, Ari ^c   Boakye, Maxwell ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Medical care; Multiple sclerosis, epidemiology; Rehabilitation

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPUTER PROGRAM; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HOME CARE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPLE SCLEROSIS; NURSING HOME; PRESCHOOL CHILD; REHABILITATION CENTER; SCHOOL CHILD; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DEMOGRAPHY; FEMALE; HOSPITALIZATION; HOSPITALS; HUMANS; INPATIENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77953332151     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000310301     Document Type: Article

References (35)

1. Hauser SL, Goodin DS: Multiple sclerosis and other demyelinating diseases; in Fauci AS, Braunwald E, Kasper DL, et al (eds): Harrison's Principles of Internal Medicine, ed 17. New York, McGraw-Hill, 2008, chapt 375.
2. Olek MJ: Differential diagnosis, clinical features, and prognosis of multiple sclerosis; in Tarsy D (ed): Multiple Sclerosis. Etiology, Diagnosis, and New Treatment Strategies. Totowa, Humana, 2005, pp 15-53.
3. Sadiq SA: Multiple sclerosis; in Rowland LP, Merritt HH (eds): Merritt's Neurology, ed 11. Philadelphia, Lippincott Williams & Wilkins, 2005, chapt 134.
4. Tremlett H, Yinshan Z, Devonshire V: Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008; 14: 314-324.
5. 1 a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801.
6. Hartung HP: Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005; 252(suppl 3):iii44-iii50.
7. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED: A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4: 419-425.
8. Green G, Todd J: 'Restricting choices and limiting independence': social and economic impact of multiple sclerosis upon households by level of disability. Chronic Illn 2008; 4: 160-172.
9. Prescott JD, Factor S, Pill M, Levi GW: Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007; 13: 44-52.
10. Agency for Healthcare Research and Quality: Calculating nationwide inpatient sample variances. Rockville, Agency for Healthcare Research and Quality, 2002.
11. Alonso A, Hernan MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129-135.
12. Cutter G, Yadavalli R, Marrie R-A, et al: Changes in the sex ratio over time in multiple sclerosis. Neurology 2007; 68:A162.
13. Orton SM, Herrera BM, Yee IM, et al: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-936.
14. Shabas D, Heffner M: Multiple sclerosis management for low-income minorities. Mult Scler 2005; 11: 635-640.
15. Murray PK, Love TE, Dawson NV, Thomas CL, Cebul RD: Rehabilitation services after the implementation of the nursing home prospective payment system: differences related to patient and nursing home characteristics. Med Care 2005; 43: 1109-1115.
16. FDA: Updates. FDA Consumer Magazine, September 1996.
17. Pleis JR, Lethbridge-Çejku M: Summary health statistics for US adults: National Health Interview Survey, 2006. Vital Health Stat 10 2007; 235: 1-153.
18. DeFrances CJ, Cullen KA, Kozak LJ: National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2007; 165: 1-209.
19. Nuyen J, Schellevis FG, Satariano WA, et al: Comorbidity was associated with neurologic and psychiatric diseases: a general practicebased controlled study. J Clin Epidemiol 2006; 59: 1274-1284.
20. Fleming ST, Blake RL Jr: Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 1994; 47: 1127-1132.
21. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008; 14: 1091-1098.
22. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxyvitamin D 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 7861-7864.
23. Forman JP, Curhan GC, Taylor EN: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008; 52: 828-832.
24. Kragt JJ, van Amerongen BM, Killestein J, et al: Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009; 15: 9-15.
25. Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM: Ultraviolet B and blood pressure. Lancet 1998; 352: 709-710.
26. Fredrikson S, Cheng Q, Jiang GX, Wasserman D: Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 2003; 22: 146-152.
27. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM: Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61: 1524-1527.
28. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S: Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62: 586-590.
29. Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R: Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006; 66: 685-692.
30. de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B: The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13: 915-928.
31. Pilz G, Wipfler P, Ladurner G, Kraus J: Modern multiple sclerosis treatment: what is approved, what is on the horizon. Drug Discov Today 2008; 13: 1013-1025.
32. Weinshenker BG, O'Brien PC, Petterson TM, et al: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
33. DeNavas-Walt C, Proctor BD, Smith J: Income, poverty, and health insurance coverage in the United States: 2006. Washington, US Government Printing Office, 2007.
34. O'Brien JA, Ward AJ, Patrick AR, Caro J: Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3: 17.
35. Heffler S, Smith S, Keehan S, Clemens MK, Zezza M, Truffer C: Health spending projections through 2013. Health Aff (Milwood) Suppl Web Exclusives:2004:W4-79-93.